Trial Profile
Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2017
Price :
$35
*
At a glance
- Drugs Azimilide (Primary)
- Indications Arrhythmias
- Focus Adverse reactions
- Sponsors Procter & Gamble
- 26 Mar 2010 New trial record